secwatch / observer
IMRX Immuneering Corp
CIK 0001790340 46 ready 8-Ks latest June 15, 2026, 4:12 PM ET RSS · JSON
Activity: QUIET 0 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)
Ready 8-Ks 46
Latest filing June 15, 2026, 4:12 PM ET
Top materiality 0.85
Event mix earnings ×19 · other_material ×15 · leadership ×6
Sentiment 22 pos · 1 neg · 23 neu
Latest earnings reported 2025-Q3
Executive change recent →

Recent 8-K filings for IMRX

Highest-materiality recent filing

Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer

March 6, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

Read filing →

Executive changes

Appointed

Andrew Gengos

Chief Financial Officer and Treasurer
IMRX · Immuneering Corp
Effective
2026-07-16
Filed
June 15, 2026, 4:12 PM ET
On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).
Role change

Mallory Morales

Senior Vice President Finance, Chief Accounting Officer
IMRX · Immuneering Corp
Effective
2026-07-16
Successor
Andrew Gengos
Filed
June 15, 2026, 4:12 PM ET
The Board also designated Mr. Gengos as the Company’s principal financial officer as of the Effective Date, succeeding Mallory Morales in such role. In her ongoing role as Senior Vice President Finance, Chief Accounting Officer, Ms. Morales will continue to serve as the Company’s principal accounting officer.
Appointed

Thomas J. Schall, Ph.D.

Director
IMRX · Immuneering Corp
Effective
2024-03-11
Filed
March 14, 2024, 7:59 PM ET
On March 11, 2024, the Board of Directors of Immuneering Corporation (“we,” “our” and “us”) appointed Thomas J. Schall, Ph.D. to serve as a member of our Board of Directors as a Class I Director.
Role change

Mallory Morales

Chief Accounting Officer and Treasurer
IMRX · Immuneering Corp
Effective
2023-07-01
Filed
June 14, 2023, 7:59 PM ET
On June 13, 2023, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Mallory Morales as the Company's Chief Accounting Officer and Treasurer, effective July 1, 2023 (the "Promotion Effective Date").
Departed

Biren Amin

Chief Financial Officer
IMRX · Immuneering Corp
Effective
2022-08-10
Successor
Mallory Morales
Filed
July 25, 2022, 7:59 PM ET
On July 20, 2022, Biren Amin notified Immuneering Corporation (the “Company”) that he plans to step down as Chief Financial Officer, principal financial officer, principal accounting officer and Treasurer of the Company to pursue another professional opportunity.
Appointed

Mallory Morales

principal financial officer, principal accounting officer and Treasurer
IMRX · Immuneering Corp
Effective
2022-08-10
Filed
July 25, 2022, 7:59 PM ET
On July 24, 2022, the Board of Directors of the Company appointed Mallory Morales, the Company’s Vice President, Finance, as principal financial officer, principal accounting officer and Treasurer of the Company, contingent and effective upon Mr. Amin ceasing to serve as the Company’s Chief Financial Officer, principal financial officer, principal accounting officer and Treasurer (the “Effective Date”).
Appointed

Diana F. Hausman, MD

Class I Director
IMRX · Immuneering Corp
Effective
2022-01-14
Filed
January 18, 2022, 6:59 PM ET
On January 14, 2022, the Board of Directors of Immuneering Corporation (the “Company”) appointed Diana F. Hausman, MD to serve as a member of the Board of Directors as a Class I Director.

Earnings & guidance

2025-Q3 EPS reported -$1.20 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event earnings

22 positive 1 negative 23 neutral

source · IMRX on sec.gov